NAV
$18.49
AUM
$13.7M
Expense Ratio
-
Dividend Yield
0.00%
Beta
2.12
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +49.84% | +58.88% | +76.20% | +247.74% | +32.15% | -4.53% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | OGN | Organon & Co Ordinary Shares | 2.39% |
| 2 | CORT | Corcept Therapeutics Inc | 2.36% |
| 3 | LQDA | Liquidia Corp Ordinary Shares | 1.84% |
| 4 | AXSM | Axsome Therapeutics Inc | 1.69% |
| 5 | DFTX | Definium Therapeutics Inc Ordinary Shares | 1.49% |
| 6 | ELVN | Enliven Therapeutics Inc | 1.48% |
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
Inception Date: 2017-11-15